In vitro metabolism studies of nomifensine monooxygenation pathways: Metabolite identification, reaction phenotyping, and bioactivation mechanism

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1767-1778

  Yu, Jian ^a   Brown, Dean G ^a   Burdette, Doug ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; FLAVIN MONOOXYGENASE; FLAVIN MONOOXYGENASE 1; FLAVIN MONOOXYGENASE 3; FLAVIN MONOOXYGENASE 5; GLUTATHIONE; NOMIFENSINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; METABOLITE; OXIDATIVE STRESS; OXYGENATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

ANIMALS; BACULOVIRIDAE; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GLUTATHIONE; HUMANS; INSECTS; MICROSOMES, LIVER; NOMIFENSINE; OXIDATION-REDUCTION; OXYGENASES; TANDEM MASS SPECTROMETRY; TRANSFECTION;

EID: 77957159047     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033910     Document Type: Article

References (23)

1. Chen W, Shockcor JP, Tonge R, Hunter A, Gartner C, and Nelson SD (1999) Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 38:8159-8166.
2. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259. (Pubitemid 29135537)
3. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
4. Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species. Arzneimittelforschung 28:58-64.
5. 14C from human urine. Br J Clin Pharmacol 9:255-264.
6. Kalgutkar AS and Soglia JR (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1:91-142.
7. Kellner HM, Baeder C, Christ O, Heptner W, Hornke I, and Ings Robert MJ (1977) Kinetics and metabolism of nomifensine in animals. Br J Clin Pharmacol 4 (Suppl 2):109S-116S.
8. Kummer H, Marti F, and Wegmann W (1985) Granulomatous hepatitis caused by nomifensine. Schweiz Med Wochenschr 115:1674-1678.
9. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, Klein K, Zanger UM, Eichelbaum M, and Fromm MF (2004) Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 14:155-164. (Pubitemid 38373109)
10. Lindberg RL and Syvälahti EK (1986) Metabolism of nomifensine after oral and intravenous administration. Clin Pharmacol Ther 39:378-383. (Pubitemid 16081403)
11. Nelson SD (1995) Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 27:147-177.
12. Nielsen JL and Lund NO (1981) Drug fever due to nomifensine treatment in patients with endogenous depression. Int Pharmacopsychiatry 16:66-68. (Pubitemid 11008099)
13. Obach RS and Dalvie DK (2006) Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes. Drug Metab Dispos 34:1310-1316.
14. Rosen GM, Singletary WV Jr, Rauckman EJ, and Killenberg PG (1983) Acetaminophen hepatotoxicity. An alternative mechanism. Biochem Pharmacol 32:2053-2059.
15. Salama A and Mueller-Eckhardt C (1985) The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med 313:469-474. (Pubitemid 15015074)
16. Salama A and Mueller-Eckhardt C (1986) Two types of nomifensine-induced immune haemolytic anaemias: drug-dependent sensitization and/or autoimmunization. Br J Haematol 64:613-620. (Pubitemid 17184271)
17. Salama A, Santoso S, and Mueller-Eckhardt C (1991) Antigenic determinants responsible for the reactions of drug-dependent antibodies with blood cells. Br J Haematol 78:535-539.
18. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
19. Silverman BR (2004) Drug metabolism, in The Organic Chemistry of Drug Design and Drug Action, 2nd ed, p 464, Elsevier Academic Press, San Diego.
20. Stonier PD and Edwards JG (2002) Nomifensine and haemolytic anemia, in Pharmacovigilance (Mann RD and Andrews EB eds) pp 155-166, Wiley, New York.
21. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
22. Thummel KE, Lee CA, Kunze KL, Nelson SD, and Slattery JT (1993) Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 45:1563-1569.
23. Yu J, Mathisen DE, Burdette D, Brown DG, Becker C, and Aharony D (2010) Identification of multiple glutathione conjugates of 8-amino-2-methyl-4-phenyl- 1,2,3,4-tetrahydroisoquinoline maleate (nomifensine) in liver microsomes and hepatocyte preparations: evidence of the bioactivation of nomifensine. Drug Metab Dispos 38:46-60.